Nona Biosciences

Highlights from the 2nd Nona Innovation Day in Boston!? On November 21, industry leaders, academics, and investors gathered for Nona's second Innovation Day, themed "Advances in Immunotherapies and ADCs." The event buzzed with insights on cutting-edge developments in biotech and oncology. Keynote Highlights: ?? Dr. Jingsong Wang, Chairman of Nona Biosciences, welcomed attendees and detailed Nona’s innovative platforms like Harbour Mice?, HCAb Plus?, and HBICE?—pioneering advancements in bi-specific antibodies, ADCs, CAR-T, and mRNA therapies. ?? Dr. Saso Cemerski from AstraZeneca shared insights on the next generation of immunotherapies and T-cell engager advancements. ??Prof. Jianzhu Chen from Massachusetts Institute of Technology presented promising CAR-NK therapies targeting oncogenic driver mutations. ?? Dr. Nimish Gera of Mythic Therapeutics, Inc. showcased their FateControl? technology, improving ADC precision and therapeutic impact. The day concluded with a networking cocktail hour and dinner, fostering collaboration and future innovations. A big thank you to all the speakers and participants for driving the future of biotech forward! Together, we’re shaping the next breakthroughs in global healthcare.?? Visit our website to learn how we empower biotherapeutic innovation: https://www.nonabio.com #Immunotherapy #ADCs #bispecific #CARTtherapy #CARNK #Oncology

Nona Biosciences is redefining CAR-T cell therapies with next-gen, fully human Heavy Chain Only Antibodies (HCAb) technology. Say goodbye to costly humanization processes—our NonaCAR? and NonaCarFx? solutions deliver high affinity, stability, and versatility for transformative cancer treatments. ?? NonaCAR?: Fully human HCAb-derived CARs with reduced immunogenicity & simplified design. ?? NonaCarFx?: Our innovative HCAb library screening platform enable the direct cloning of HCAb libraries into CAR-lentiviral vectors that takes CAR-T to new heights! Join us at the cutting edge of CAR-T innovation: https://lnkd.in/efS7G9Yj #celltherapy #carttherapy #cartcelltherapy #immunotherapy #immunooncology

???????????????????? ????????? ???????? ?????? ???????? ???? ?????? ???????????????? ????????????????????: - ?????????? ??????????????????????????: Varying antigen expression across tumor cells can lead to inconsistent results. - ?????????????????????????????? ????????????????????: ADCs must penetrate cells and release payloads effectively within the tumor microenvironment. - ???????????????????? ????????????????????: Tumor cells can block ADCs, impacting efficacy and limiting therapeutic potential. Nona Biosciences develops internalization-independent custom linkers with high stability, precise release, and payload compatibility, designed specifically for complex tumor environments. Reach out to explore how we can enhance your ADC pipeline! https://lnkd.in/eyHStt4y #ADC #antibodies #drugdevelopment #antibodydiscovery #HCAb #heavychainantibodies #FullyHuman

A Breakthrough in Medicine: Fully Human HCAb-Based mRNA-LNP ?? mRNA-encoding biologics are changing the game in modern medicine! At Nona Biosciences, we’re harnessing cutting-edge mRNA technology to bring the future of therapeutics to life. Here's how our fully human HCAb-based mRNA-LNP platform is making waves: https://nonabio.com/mrna ?? What Sets Our Technology Apart? 1?? Exceptional Cytotoxicity: Our HCAb TAA x CD3 mRNA-LNP exhibits remarkable cytotoxic effects on TAA-expressing target cells. 2?? Specific Killing Effect: Precision matters! The TAA x CD3 mRNA-LNP targets TAA-positive cells specifically, reducing off-target risks and increasing safety. 3?? Distinct Killing Pattern:?? This approach delivers a unique killing pattern compared to traditional methods, maximizing therapeutic potential. 4?? Potent Anti-Tumor Efficacy:?? In vivo studies show that our mRNA-LNP therapy significantly reduces tumor volume, with efficacy scaling with dosage. With the Harbour HCAb Mice? platform at the core, our innovative solution is shaping the future of targeted, effective cancer treatments. ???? ?? Stay tuned as we continue to advance next-gen therapies! https://nonabio.com/mrna #mRNA #mRNATherapy #CancerTherapy #HCAb #PrecisionMedicine #Antibodies

?? Unlock the Future of CAR-T Therapy with Nona Biosciences! ?? Are you looking to stay at the cutting edge of cancer treatment advancements? Our latest white paper dives deep into how Nona Biosciences is transforming CAR-T therapy using state-of-the-art, fully human heavy chain antibodies (HCAbs) for superior efficacy and safety. Highlights of our innovations: - ??????????????? ????????????????????: Leverages fully human HCAbs to reduce immunogenicity and maximize therapeutic impact. - ??????????????????? ????????????????: Pioneering direct CAR-function-based HCAb screening for faster, more efficient development. - ????????????? ????????????????????: Achieve single-day antibody discovery, optimizing labor and throughput. - ?????????????????????????? ???? ?????????? ????????????????????????????????: Ensures robust, high-performance CAR-T cell therapy. Ready to explore the science behind these breakthroughs? Download the full white paper to learn more about our integrated technologies and how we're driving the future of CAR-T therapies. ?? https://lnkd.in/eNiMxrrF #HCAb #heavychainonly #CARTcell #CART #CARTTherapy #Biotechnology #AntibodyDiscovery #CancerTreatment #Innovation

??TCRm antibodies are revolutionizing cancer immunotherapy by combining T-cell receptor precision with antibody versatility, enabling the targeting of a wider range of intracellular antigens. ??These antibodies can recognize antigens presented by MHC molecules, achieving subnanomolar affinity for greater therapeutic impact. With mechanisms like ADCC, CDC, and peptide-MHC targeting, TCRm antibodies enhance tumor cell destruction. ??They also provide antibody-like stability and a long half-life, while being easier to manufacture than traditional TCR-based therapies, making them scalable for large-scale application. Nona Biosciences is at the forefront of this innovation, advancing cancer treatment with highly specific and promising TCRm designs. Learn more: https://lnkd.in/eT-_VkKp

Introducing our custom linker Solution for advanced bioconjugate therapies While off-the-shelf linkers offer convenience in ADC development, overcoming therapeutic challenges such as internalization efficiency and targeted release requires custom solutions. Nona Biosciences screens peptides based on natural substrates and tumor-associated enzyme structures to develop linkers that optimize payload release specifically within the tumor microenvironment. Contact us today to help your ADCs reach their full potential: https://lnkd.in/eyHStt4y #ADC #antibodies #drugdevelopment #antibodydiscovery #HCAb #heavychainantibodies

The moment is finally here! Join us at Booth #417 and then head over to the Town & Country Room D at 12:30 PM to discover our groundbreaking Novel Enzyme Cleavable Linker for the Development of Next-Gen ADCs against Solid Tumors. ? Whether you have just a brief moment to drop by or want to engage in deeper conversation, we're here to explore how we can help you advance your next ADC therapeutic. ? Looking forward to seeing you there! ? #ADC #antibodies #drugdevelopment #antibodydiscovery #HCAb #heavychainantibodies

TCRm antibodies represent a breakthrough in cancer immunotherapy, combining T-cell receptor specificity with antibody properties to target a wider range of intracellular antigens. Unlike traditional therapies, TCRm antibodies offer unique advantages: - ?????????????? ?????????????? ??????????????????: Recognize intracellular antigens presented by MHC molecules, expanding beyond surface targets. - ???????????? ????????????????: Achieve subnanomolar affinity, potentially enhancing therapeutic effectiveness. - ???????????????? ???????????????????? ???? ???????????? (??????): Enable tumor cell killing through ADCC, CDC, and specific peptide-MHC recognition. - ????????????????-???????? ????????????????????????: Offer a long half-life and stability for sustained action. - ???????????????? ????????????????????: Easier to manufacture than TCR-based therapies, ideal for large-scale applications. Nona Biosciences' TCRm antibodies are leading the way with innovative design and high specificity, holding strong promise for advancing cancer treatment.?? Learn more: https://lnkd.in/eT-_VkKp #TCRm #TCRmimic #antibodies #HCAb #CancerResearch #Immunotherapy #Biotech

Looking forward to PEGS Europe! If you’re working on Antibody drug development with specific interests of TCR Mimic Antibody / Single Domain Antibody applications in Immunotherapies, ?visit me at poster section ·??????A085?Single Domain CD3 Antibody Enables Next-Generation T Cell Engagers for Enhanced Immunotherapies ·??????B080 Discovery of T-Cell Receptor Mimic Antibody Derived T-Cell Engager I will be talking about how our Harbour mice platform leverage the antibody based immunotherapies developments Excited to share ideas and learn from everyone there. Hope to see you! https://lnkd.in/e6FvjGpE #FullyHumanAntibody #PEGSEurope #ImmunoTherapy #Nanobody #TCRMimicAntibody